Navigation Links
Charleston Laboratories, Inc. Announces Senior Global Regulatory Hire
Date:2/15/2017

JUPITER, Fla., Feb. 15, 2017 /PRNewswire/ -- Charleston Laboratories, Inc. announced today that Mark A. Mannebach, Ph.D., R.Ph has joined its team as its Vice President of Global Regulatory Affairs & Quality Assurance.  In his role, Mark will oversee and manage all regulatory submissions and renewals and will be responsible for developing the technical requirements of supply and quality agreements and other external contracts, specifically in relation to Charleston Laboratories' pipeline of products that address unmet needs such as Opioid-Induced Nausea and Vomiting (OINV) and Migraine-Induced Nausea and Vomiting (MINV), including co-promotion activities under its collaboration with Daiichi Sankyo.

"We're proud to add Mark to our already impressive senior leadership team," said Mr. Paul Bosse, President and Chief Executive Officer at Charleston Laboratories.  "Mark's experience in regulatory and quality, coupled with his experience in the pain management industry, will make him a key member of the team."

Mark has more than 30 years of experience in the pharmaceutical industry in a variety of leadership roles at various major pharmaceutical companies including Parke-Davis/Warner-Lambert, Pharmacia, Baxter and Pfizer. For the past 8 years, Mark was the Vice President of Global Regulatory Affairs at Mallinckrodt where he spent a significant amount of his time overseeing the pain management portfolio.  Mark has extensive experience working with the Division of Anesthesia, Analgesia, and Addiction Products (DAAAP) on a number of NDAs including 505(b)(2) applications.  Mark had responsibility for the NDAs for the approved pain products Exalgo, Pennsaid (both 1.5% & 2% topical solutions), Xartemis XR, and Ofirmev.

"I was intrigued by the opportunity that Charleston Laboratories' pipeline and commercial strategy provides me professionally, to continue working in pain management," stated Dr. Mannebach.  "I'm honored to join a team with such deep experience and a commitment to clinical and commercial excellence."

About Charleston Laboratories, Inc.
Charleston Laboratories, Inc. is a privately held, specialty pharmaceutical company focused on the research, development and commercialization of novel pain products to prevent the burdensome side effects related to opioid analgesics and other analgesic products.  In August 2014, the Company entered a strategic collaboration with Daiichi Sankyo for the development and U.S. commercialization of Charleston Laboratories' investigational hydrocodone-based products, including its lead candidate CL-108.

Charleston Laboratories' product pipeline seeks to address unmet needs in Opioid-Induced Nausea and Vomiting (OINV), Postoperative Nausea and Vomiting (PONV), Chemotherapy-Induced Nausea and Vomiting (CINV), Radiation-Induced Nausea and Vomiting (RINV), and Migraine-Induced Nausea and Vomiting (MINV).  Charleston Laboratories intends to introduce novel pain therapies that reduce the burdensome side effects related to opioid analgesics and other products. For more information, please visit www.charlestonlabs.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/charleston-laboratories-inc-announces-senior-global-regulatory-hire-300407320.html


'/>"/>
SOURCE Charleston Laboratories, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Receive Complete Response Letter from FDA for New Drug Application for CL-108 (hydrocodone, acetaminophen, promethazine) Tablets for Oral Use
2. AAIPharma Services Corp. / Cambridge Major Laboratories, Inc. kondigt uitbreiding mogelijkheden en capaciteiten voor steriele productie medicijnen in Charleston, SC aan
3. AAIPharma Services Corp. / Cambridge Major Laboratories, Inc. Announces Expanded Capabilities and Capacity for Sterile Drug Product Manufacturing in Charleston, SC
4. The Business Development Board of Palm Beach Plays Key Role in Charleston Laboratories, Inc. Expansion
5. Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Phase 3 Study of CL-108 Met Primary Endpoints
6. Charleston Area Medical Center Integrates Smart Pump Technology to Advance Patient Safety
7. Charleston Laboratories, Inc. Announces Completion of a Second Phase 3 Clinical Trial on its Lead Product, CL-108, and the Appointment of Dr. Raymond Dionne to its Scientific Advisory Board
8. Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charlestons Second Product, CL-H1T
9. Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Three Poster Presentations at American Pain Society Annual Meeting
10. Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Completion of a Pharmacokinetics Study on CL-108
11. Charleston Laboratories, Inc. Announces Key Clinical Updates for Novel Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... , Sept. 5, 2017 Sapheneia and Scannerside ... solution. Scannerside DoseCheck is a third-party Vendor neutral CT ... scanners and allows compliance with current MITA standards. ... XR 29 DoseCheck solution is specifically designed to provide ... of potential radiation doses over a predefined threshold. Scannerside ...
(Date:9/5/2017)... LONDON , Sept. 5, 2017  Just 18 ... Valid Insight is pleased to announce the appointment of ... Tammy Wynne , Dominic Jones-Phillips and ... from industry. ... a team of market access writers. She has over ...
(Date:9/1/2017)... 2017  Explorers Like Us ( https://explorerslikeus.com/ ) is embarking ... — and deliver these experiences as part of Life Environments™, ... and heal better. ... While nothing beats a walk, jog or simply playing ... Environments™ is the next best thing when getting there isn’t ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... “Psalms of Humidity”: is ... of mind and move the readers one step closer to God. “Psalms of Humidity” ... that his mistakes that have been made within his life are the very same ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... jiu-jitsu community have raised more than $15,000 in just a couple of weeks ... submission grappling matches and world-class instructor seminars, organizers expect to double those initial ...
(Date:9/19/2017)... ... 2017 , ... Peter Chandonait, Abt Associates Principal Scientist and ... Africa Indoor Residual Spraying (AIRS) Project , has been named the Grand Prize ... Award, a USAID Catalyst Award, recognizes USAID staff and implementing partners who have ...
(Date:9/19/2017)... ... , ... MelaKids, a Laredo-based company, has introduced a new concept for children’s ... gives us a full supply of melanin – in the back of the eye ... pigment; however, around the age of thirty, we develop a yellow-brown pigment in the ...
(Date:9/19/2017)... RESTON, Va (PRWEB) , ... September 19, 2017 , ... ... on the use of health IT to create efficiencies in healthcare information exchange and ... announced the release of their latest industry white paper, entitled Barriers to Adoption ...
Breaking Medicine News(10 mins):